TRANSCODE THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
TRANSCODE THERAPEUTICS INC. - More news...
TRANSCODE THERAPEUTICS INC. - More news...
- TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
- TransCode Therapeutics, Inc. Announces $8 Million Private Placement
- TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
- TransCode Therapeutics Open Letter to Shareholders
- TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
- TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
- TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
- TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
- TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
- TransCode Therapeutics, Inc. Announces Closing of Public Offering
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering
- TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
- TransCode Therapeutics Open Letter to Shareholders
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
- TransCode Therapeutics Reports 2023 Results; Provides Business Update
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
- TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
- TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
- TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
- TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
- TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
